Note: Xilio described the IRA in a risk section entitled “Current and future legislative efforts may limit the prices for our products, if and when they are licensed for marketing, and that could materially impact our ability to generate revenues”
All entries for: Biologic
April 27, 2023
Eli Lilly & Company
Negative Outlook
Indianapolis, IN
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic
April 27, 2023
Bristol Myers Squibb
Negative Outlook
Princeton, NJ
10,001-50,000 employees
10001-50000 employees
Drug Type: Biologic, Small Molecule
April 25, 2023
Biogen
Negative Outlook
Cambridge, MA
5,001-10,000 employees
5001-10000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
November 9, 2022
Xilio Therapeutics
Negative Outlook
Waltham, MA
51-200 employees
51-200 employees
Disease Area: Oncology
Drug Type: Biologic
November 9, 2022
Mirum Pharmaceuticals
Negative Outlook
Foster City, CA
51-200 employees
51-200 employees
Likely to Have “Significant Impact”: “These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry” Impact to Livmarli: “Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from third-party payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize Livmarli and our other product candidates, if approved.”
Disease Area: Rare Diseases
Drug Type: Biologic
November 9, 2022
Context Therapeutics
Negative Outlook
Philadelphia, PA
1-50 employees
1-50 employees
Concern Over Ability to Sell Product: “The passage of the Inflation Reduction Act of 2022 may negatively impact our ability to sell our product candidates, if approved, profitably”
Disease Area: Oncology
Drug Type: Biologic
November 9, 2022
Beigene
Negative Outlook
Cambridge, MA
5,001-10,000 employees
5001-10000 employees
Concern on Impact to Commercial Market: “Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our medicines and drug candidates”
Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
November 8, 2022
Zymeworks
Negative Outlook
Middletown, DE
201-500 employees
201-500 employees
Concerns over Revenue Generation: “The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcarereforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved”
Disease Area: Multiple, Oncology, Therapeutics
Drug Type: Biologic
November 8, 2022
Sage Therapeutics
Negative Outlook
Cambridge, MA
501-1,000 employees
501-1000 employees
Concerns on Impact to Commercial Market & Development Decisions: “These risks as to pricing may further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if the pricing of any of our products are the subject of Medicare price negotiations. As a result, these risks may also impact the development decisions we make with respect to our products.”
Disease Area: Neurological Diseases
Drug Type: Biologic
November 8, 2022
Adicet Bio
Negative Outlook
Boston, MA
51-200 employees
51-200 employees
Concerns on Profitability: “There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. For example, in August 2022, the Inflation Reduction Act of 2022 (the “IRA”) was signed into law… The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates”
Disease Area: Oncology
Drug Type: Biologic
